Oncolytic virus Ad-TD-nsIL-12 inhibits glioma growth and reprograms the tumor immune microenvironment
- 16 November 2023
- journal article
- research article
- Published by Elsevier in Life Sciences
- Vol. 336, 122254
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82101932)
This publication has 32 references indexed in Scilit:
- Interleukin 12: still a promising candidate for tumor immunotherapy?Cancer Immunology, Immunotherapy, 2014
- IL-12 family cytokines: immunological playmakersNature Immunology, 2012
- Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agentsVirology, 2009
- Human Adenovirus Replicates in Immunocompetent Models of Pancreatic Cancer in Syrian HamstersHuman Gene Therapy, 2007
- Syrian Hamster as a Permissive Immunocompetent Animal Model for the Study of Oncolytic Adenovirus VectorsCancer Research, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- A Phase I Open-Label, Dose-Escalation, Multi-Institutional Trial of Injection with an E1B-Attenuated Adenovirus, ONYX-015, into the Peritumoral Region of Recurrent Malignant Gliomas, in the Adjuvant SettingMolecular Therapy, 2004
- NK and CD8+ T cell‐mediated eradication of poorly immunogenic B16‐F10 melanoma by the combined action of IL‐12 gene therapy and 4‐1BB costimulationInternational Journal of Cancer, 2004
- Replication-selective adenoviruses as oncolytic agentsJournal of Clinical Investigation, 2000
- Antitumor and antimetastatic activity of interleukin 12 against murine tumors.Journal of Experimental Medicine, 1993